|
US5439686A
(en)
*
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
|
US5919816A
(en)
*
|
1994-11-14 |
1999-07-06 |
Bionumerik Pharmaceuticals, Inc. |
Formulations and methods of reducing toxicity of antineoplastic agents
|
|
US8853260B2
(en)
*
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US20020155999A1
(en)
*
|
1998-04-30 |
2002-10-24 |
Han In Suk |
Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
|
|
US7314637B1
(en)
|
1999-06-29 |
2008-01-01 |
Neopharm, Inc. |
Method of administering liposomal encapsulated taxane
|
|
US6197831B1
(en)
*
|
1999-02-09 |
2001-03-06 |
Bionumerik Pharmaceuticals, Inc. |
Method of treating septic shock
|
|
US6075053A
(en)
*
|
1999-02-09 |
2000-06-13 |
Bionumerik Pharmaceuticals, Inc. |
Method of reducing or reversing neuropathy
|
|
US6395481B1
(en)
*
|
1999-02-16 |
2002-05-28 |
Arch Development Corp. |
Methods for detection of promoter polymorphism in a UGT gene promoter
|
|
US20030036513A1
(en)
*
|
1999-02-16 |
2003-02-20 |
Yurkow Edward J. |
Method for treating cancer
|
|
GB9904386D0
(en)
*
|
1999-02-25 |
1999-04-21 |
Pharmacia & Upjohn Spa |
Antitumour synergistic composition
|
|
DE60031268T2
(de)
*
|
1999-04-14 |
2007-05-24 |
Dana-Farber Cancer Institute, Inc., Boston |
Verfahren und zusammansetzung zur behandlung von krebs
|
|
US20050192360A1
(en)
*
|
1999-04-14 |
2005-09-01 |
Li Chiang J. |
Method of treatment of pancreatic cancer
|
|
US20050222246A1
(en)
*
|
1999-04-14 |
2005-10-06 |
Li Chiang J |
Beta-lapachone is a broad spectrum anti-cancer agent
|
|
AU777528B2
(en)
*
|
1999-04-22 |
2004-10-21 |
Abraxis Bioscience, Llc |
Long term administration of pharmacologically active agents
|
|
MY164077A
(en)
*
|
1999-05-13 |
2017-11-30 |
Pharma Mar Sa |
Compositions and uses of et743 for treating cancer
|
|
US6034126A
(en)
*
|
1999-05-24 |
2000-03-07 |
Bionumerik Pharmaceuticals, Inc. |
Method for treating glycol poisoning
|
|
GB9916882D0
(en)
*
|
1999-07-19 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Antitumor synergistic composition
|
|
US6294546B1
(en)
*
|
1999-08-30 |
2001-09-25 |
The Broad Of Trustees Of The Leland Stanford Junior University |
Uses of diterpenoid triepoxides as an anti-proliferative agent
|
|
HK1049787B
(en)
|
1999-10-01 |
2014-07-25 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
WO2001036048A1
(en)
*
|
1999-11-15 |
2001-05-25 |
Parker Hughes Institute |
Phorboxazole derivatives for treating cancer
|
|
US6890946B2
(en)
*
|
1999-12-23 |
2005-05-10 |
Indiana University Research And Technology Corporation |
Use of parthenolide to inhibit cancer
|
|
AU2000239101A1
(en)
*
|
2000-03-22 |
2001-10-03 |
Neopharm, Inc. |
A method of administering liposomal encapsulated taxane
|
|
GB0011927D0
(en)
*
|
2000-05-17 |
2000-07-05 |
Inst Biomar Sa |
New use of citreamicins
|
|
GB0011903D0
(en)
*
|
2000-05-18 |
2000-07-05 |
Astrazeneca Ab |
Combination chemotherapy
|
|
US20050197405A1
(en)
*
|
2000-11-07 |
2005-09-08 |
Li Chiang J. |
Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
|
|
CN1531424A
(zh)
|
2000-11-09 |
2004-09-22 |
����˹��ҩ�﹫˾ |
Sn-38类脂络合物和应用的方法
|
|
WO2002056755A2
(en)
*
|
2001-01-19 |
2002-07-25 |
Bionumerik Pharmaceuticals, Inc. |
Method for treating cancer
|
|
US6620843B2
(en)
*
|
2001-01-19 |
2003-09-16 |
Pharmagenesis |
Anticancer treatment using triptolide prodrugs
|
|
US20030149096A1
(en)
*
|
2001-02-05 |
2003-08-07 |
Pezzuto John M. |
Cancer chemopreventative compounds and compositions and methods of treating cancers
|
|
EP1368034A1
(en)
*
|
2001-03-06 |
2003-12-10 |
Bristol-Myers Squibb Company |
Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
|
|
PT1372650E
(pt)
*
|
2001-03-19 |
2009-02-25 |
Novartis Ag |
Associações compreendendo um agente antidiarreico e uma epotilona ou um derivado de epotilona
|
|
US6756063B2
(en)
*
|
2001-03-29 |
2004-06-29 |
Zoltan Laboratories, Llc |
Methods and compositions for the treatment of human and animal cancers
|
|
US7053072B2
(en)
|
2001-05-11 |
2006-05-30 |
Medimmune Oncology, Inc. |
Methods for the administration of amifostine and related compounds
|
|
US20030045515A1
(en)
*
|
2001-05-24 |
2003-03-06 |
Lise Binderup |
Combination medicament for treatment of neoplastic diseases
|
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
|
US8048917B2
(en)
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
US7186855B2
(en)
*
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
US6476068B1
(en)
|
2001-12-06 |
2002-11-05 |
Pharmacia Italia, S.P.A. |
Platinum derivative pharmaceutical formulations
|
|
US6596320B1
(en)
*
|
2002-01-11 |
2003-07-22 |
Bionumerik Pharmaceuticals, Inc. |
Method for treating cancer having greater efficacy and reduced adverse effects
|
|
US6816571B2
(en)
*
|
2002-02-06 |
2004-11-09 |
L-3 Communications Security And Detection Systems Corporation Delaware |
Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
|
|
AU2003220219A1
(en)
|
2002-03-15 |
2003-09-29 |
Schering Corporation |
Methods of modulating cd200 receptors
|
|
US8710095B2
(en)
*
|
2002-04-30 |
2014-04-29 |
Bionumerik Pharmaceuticals, Inc. |
Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
|
|
JP4625694B2
(ja)
*
|
2002-05-17 |
2011-02-02 |
レオ ファーマ アクティーゼルスカブ |
シアノグアニジンプロドラッグ
|
|
US7253193B2
(en)
*
|
2002-05-17 |
2007-08-07 |
Leo Pharma A/S |
Cyanoguanidine prodrugs
|
|
US20060014804A1
(en)
*
|
2002-05-17 |
2006-01-19 |
Leo Pharma A/S |
Cyanoguanidine prodrugs
|
|
US20040038904A1
(en)
*
|
2002-05-21 |
2004-02-26 |
Angela Ogden |
Method of treating multiple sclerosis
|
|
JP4680589B2
(ja)
*
|
2002-05-31 |
2011-05-11 |
ファーマジェネシス, インコーポレイテッド |
アポトーシスおよび免疫抑制の調節のためのトリプトリド誘導体
|
|
US20040127435A1
(en)
*
|
2002-08-02 |
2004-07-01 |
Regents Of The University Of California |
Uses for inhibitors of inosine monophosphate dehydrogenase
|
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
|
AU2003296897A1
(en)
*
|
2002-08-20 |
2004-05-04 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
|
NZ538584A
(en)
*
|
2002-09-05 |
2007-05-31 |
Bharat Serums & Vaccines Ltd |
Stable liquid composition of oxazaphosphorine, mesna and etherified beta-cyclodextrin
|
|
US7025745B2
(en)
*
|
2002-10-07 |
2006-04-11 |
Advanced Cardiovascular Systems, Inc. |
Method of making a catheter balloon using a tapered mandrel
|
|
WO2004054569A1
(en)
*
|
2002-12-16 |
2004-07-01 |
Council Of Scientific And Industrial Research |
Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
|
|
US20040203034A1
(en)
*
|
2003-01-03 |
2004-10-14 |
The University Of Chicago |
Optimization of cancer treatment with irinotecan
|
|
KR20050105451A
(ko)
*
|
2003-02-03 |
2005-11-04 |
네오팜 인코포레이티드 |
안정한 멸균 여과가능한 리포좀 캡슐화 탁산 및 다른항종양제
|
|
JP2006526412A
(ja)
*
|
2003-05-30 |
2006-11-24 |
ユニバーシティ オブ シカゴ |
イリノテカン毒性を推定する方法および組成物
|
|
US20040266808A1
(en)
*
|
2003-06-27 |
2004-12-30 |
Kamen Barton A. |
Treatment of antifolate neurotoxicity
|
|
EP2263694B1
(en)
*
|
2003-09-25 |
2013-06-12 |
Astellas Pharma Inc. |
Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
|
|
US7820834B2
(en)
*
|
2003-12-24 |
2010-10-26 |
Pharmagenesis, Inc. |
Triptolide 5,6-derivatives as immunomodulators and anticancer agents
|
|
EP1722806A4
(en)
*
|
2004-02-09 |
2009-09-16 |
Pharmagenesis Inc |
METHOD OF ISOLATING TRIPTOLIDE COMPOUNDS FROM TRIPTERYGIUM WILFORDII
|
|
US20050187288A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Chiang Li |
Beta-lapachone and methods of treating cancer
|
|
US20050192247A1
(en)
*
|
2004-02-23 |
2005-09-01 |
Li Chiang J. |
Method of treating cancers
|
|
ES2385716T3
(es)
*
|
2004-03-02 |
2012-07-30 |
Pharmagenesis, Inc. |
Derivados en el anillo de lactona de triptolida como inmunomoduladores y agentes anticáncer
|
|
US20090247475A1
(en)
*
|
2004-03-05 |
2009-10-01 |
The Regents Of The University Of California |
Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
|
|
US7200207B2
(en)
*
|
2004-03-13 |
2007-04-03 |
Intrado Inc. |
Communication network for providing emergency services
|
|
US7605137B2
(en)
*
|
2004-03-26 |
2009-10-20 |
Vion Pharmaceuticals, Inc. |
Combination therapy comprising cloretazine
|
|
US20090111735A1
(en)
*
|
2004-05-12 |
2009-04-30 |
Bionumerik Pharmaceuticals, Inc. |
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
|
|
US20050256055A1
(en)
*
|
2004-05-12 |
2005-11-17 |
Hausheer Frederick H |
Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
|
|
JP4433918B2
(ja)
*
|
2004-07-15 |
2010-03-17 |
コニカミノルタエムジー株式会社 |
画像形成方法
|
|
ATE552233T1
(de)
*
|
2004-08-20 |
2012-04-15 |
Univ Virginia Patent Found |
T-typ-calciumkanalinhibitoren
|
|
US20060063742A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Hausheer Frederick H |
Method of treatment for or protection against lymphedema
|
|
TWI366459B
(en)
*
|
2004-09-28 |
2012-06-21 |
Ind Tech Res Inst |
Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
|
|
US8617906B2
(en)
*
|
2004-10-13 |
2013-12-31 |
Pharmagenesis, Inc. |
Identification and screening of triptolide target molecules
|
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
|
ES2572777T3
(es)
*
|
2004-12-22 |
2016-06-02 |
Leo Pharma A/S |
Compuestos novedosos de cianoguanidina
|
|
EP1790343A1
(en)
*
|
2005-11-11 |
2007-05-30 |
Emotional Brain B.V. |
Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
|
|
DK1991237T3
(en)
*
|
2005-12-13 |
2015-04-27 |
Bionumerik Pharmaceuticals Inc |
Chemoprotective methods and compositions
|
|
US8143236B2
(en)
*
|
2005-12-13 |
2012-03-27 |
Bionumerik Pharmaceuticals, Inc. |
Chemoprotective methods
|
|
US8895531B2
(en)
*
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
|
US8168661B2
(en)
*
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8168662B1
(en)
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8178564B2
(en)
|
2006-11-06 |
2012-05-15 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
RU2009133447A
(ru)
*
|
2007-02-09 |
2011-03-20 |
Пониард Фармасьютикалз, Инк. (Us) |
Дозированная форма пикоплатина
|
|
US20110033528A1
(en)
*
|
2009-08-05 |
2011-02-10 |
Poniard Pharmaceuticals, Inc. |
Stabilized picoplatin oral dosage form
|
|
CN101657203B
(zh)
*
|
2007-03-02 |
2012-09-05 |
卧龙岗大学 |
抗癌药的组合物及递送方法
|
|
US20100260832A1
(en)
*
|
2007-06-27 |
2010-10-14 |
Poniard Pharmaceuticals, Inc. |
Combination therapy for ovarian cancer
|
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
|
JP2010533714A
(ja)
*
|
2007-07-16 |
2010-10-28 |
ポニアード ファーマシューティカルズ, インコーポレイテッド |
ピコプラチンのための経口製剤
|
|
CA2701071C
(en)
*
|
2007-09-26 |
2018-03-27 |
Gemin X Pharmaceuticals Canada Inc. |
Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
|
|
EP2219619B1
(en)
*
|
2007-11-20 |
2020-07-15 |
Lankenau Institute for Medical Research |
Disulfide chemotherapeutic agents and methods of use thereof
|
|
AU2009210656A1
(en)
*
|
2008-02-08 |
2009-08-13 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin and cetuximab to treat colorectal cancer
|
|
US7998967B2
(en)
*
|
2008-03-03 |
2011-08-16 |
Tosk, Incorporated |
Methotrexate adjuvants to reduce toxicity and methods for using the same
|
|
EP2259844A4
(en)
*
|
2008-03-05 |
2012-02-01 |
Vicus Therapeutics Llc |
COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES
|
|
EP2252246B1
(en)
*
|
2008-03-14 |
2014-06-18 |
Bionumerik Pharmaceuticals, Inc. |
Chemoprotective methods and compositions
|
|
CN102014891B
(zh)
*
|
2008-03-14 |
2013-12-18 |
比奥纽默里克药物公司 |
增加癌症患者存活时间的化合物的组合物和使用方法
|
|
US9320760B2
(en)
*
|
2008-03-14 |
2016-04-26 |
Bionumerik Pharmaceuticals, Inc. |
Compositions and methods of use of compounds to increase cancer patient survival time
|
|
EP2249825B1
(en)
*
|
2008-03-14 |
2015-10-07 |
Bionumerik Pharmaceuticals, Inc. |
Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
|
|
US8697391B2
(en)
|
2009-05-15 |
2014-04-15 |
Lankenau Institute For Medical Research |
Method of determining cell number or viability using hydroxyethyldisulfide
|
|
CA2787673A1
(en)
|
2010-03-01 |
2011-09-09 |
Tau Therapeutics Llc |
Cancer diagnosis and imaging
|
|
JP5918227B2
(ja)
*
|
2010-07-09 |
2016-05-18 |
ウェリケム・バイオテック・インコーポレイテッドWelichem Biotech Inc. |
転移性腫瘍の生長抑制のための新規なスルホンアミド化合物
|
|
US9271952B2
(en)
*
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
CN102871991B
(zh)
*
|
2012-10-24 |
2014-06-18 |
中国医学科学院放射医学研究所 |
二甲双胍在对放化疗损伤起保护作用的药物中的应用
|
|
EP3027212A1
(en)
*
|
2013-08-02 |
2016-06-08 |
Children's Hospital Medical Center |
Compositions and methods for treating disease states associated with activated t cells and/or b cells
|
|
US9470029B2
(en)
|
2014-05-30 |
2016-10-18 |
Pella Corporation |
Casement pivot arm roller hinge
|
|
IL280619B2
(en)
|
2015-07-07 |
2023-10-01 |
H Lundbeck As |
Phosphodiesterase 9 inhibitors with an imidazo triazinon or imidazo pyrazinone skeleton for the treatment of peripheral diseases
|
|
IL258476B2
(en)
|
2015-10-02 |
2023-04-01 |
Complexa Inc |
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
|
|
EP4349403A3
(en)
|
2018-05-25 |
2024-06-05 |
Cardurion Pharmaceuticals, Inc. |
Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
|
|
MA53501A
(fr)
|
2018-08-31 |
2021-07-07 |
Imara Inc |
Inhibiteurs de pde9 pour le traitement de la drépanocytose
|